Abstract
Background. A 57-year-old woman was referred to a nephrology clinic because of chronic hypokalemia. She had a history of polycystic kidney disease, resistant hypertension, atrial fibrillation, type 2 diabetes, stroke, and end-stage renal disease, and had received a kidney transplant from a deceased donor at the age of 48 years. At presentation, the patient described symptoms of chronic fatigue and muscle aches, but she did not report pareses. Her medications included four antihypertensive agents, glucose-lowering drugs, immunosuppressants, digoxin, a coumarin derivative, and potassium chloride.
Investigations. Full history, physical examination, laboratory testing of blood and urine, including aldosterone-torenin ratio, and a saline infusion test.
Diagnosis. Primary aldosteronism.
Management. Treatment with spironolactone resulted in prompt control of hypertension and hypokalemia, allowing discontinuation of potassium chloride and reduction in antihypertensive medication.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Mulatero, P. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J. Clin. Endocrinol. Metab. 89, 1045–1050 (2004).
Rossi, G. P. et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J. Am. Coll. Cardiol. 48, 2293–2300 (2006).
Schwartz, G. L. & Turner, S. T. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin. Chem. 51, 386–394 (2005).
Yang, C. W. et al. Primary aldosteronism detected after renal transplantation. Am. J. Nephrol. 14, 220–222 (1994).
Catena, C. et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch. Intern. Med. 168, 80–85 (2008).
Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243–1248 (2005).
Jaffe, I. Z. & Mendelsohn, M. E. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ. Res. 96, 643–650 (2005).
Leopold, J. A. et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13, 189–197 (2007).
Sowers, J. R., Whaley-Connell, A. & Epstein, M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann. Intern. Med. 150, 776–783 (2009).
Rucker, D. & Tonelli, M. Cardiovascular risk and management in chronic kidney disease. Nat. Rev. Nephrol. 5, 287–296 (2009).
Funder, J. W. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 3266–3281 (2008).
Berl, T., Katz, F. H., Henrich, W. L., de Torrente, A. & Schrier, R. W. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 14, 228–235 (1978).
Hene, R. J., Boer, P., Koomans, H. A. & Mees, E. J. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 21, 98–101 (1982).
Ecder, T. & Schrier, R. W. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J. Am. Soc. Nephrol. 12, 194–200 (2001).
Rossi, G. P., Pessina, A. C. & Heagerty, A. M. Primary aldosteronism: an update on screening, diagnosis and treatment. J. Hypertens. 26, 613–621 (2008).
Ethier, J. H., Kamel, K. S., Magner, P. O., Lemann, J. Jr & Halperin, M. L. The transtubular potassium concentration in patients with hypokalemia and hyperkalemia. Am. J. Kidney Dis. 15, 309–315 (1990).
Biglieri, E. G. Rare causes of adrenocortical hypertension. Cardiology 72 (Suppl. 1), 70–75 (1985).
Rossi, G. P. et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 48, 232–238 (2006).
Corcoran, A. C., Dustan, H. P. & Page, I. H. Renal function in primary aldosteronism. J. Clin. Invest. 35, 1357–1363 (1956).
Sechi, L. A. et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 295, 2638–2645 (2006).
Sechi, L. A., Di Fabio, A., Bazzocchi, M., Uzzau, A. & Catena, C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J. Clin. Endocrinol. Metab. 94, 1191–1197 (2009).
Catena, C. et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin. J. Am. Soc. Nephrol. 2, 722–731 (2007).
Linas, S. L. & Dickmann, D. Mechanism of the decreased renal blood flow in the potassium-depleted conscious rat. Kidney Int. 21, 757–764 (1982).
Reungjui, S. et al. Hypokalemic nephropathy is associated with impaired angiogenesis. J. Am. Soc. Nephrol. 19, 125–134 (2008).
Tolins, J. P., Hostetter, M. K. & Hostetter, T. H. Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. J. Clin. Invest. 79, 1447–1458 (1987).
Tsao, T. et al. Expression of insulin-like growth factor-I and transforming growth factor-beta in hypokalemic nephropathy in the rat. Kidney Int. 59, 96–105 (2001).
Cremer, W. & Bock, K. D. Symptoms and course of chronic hypokalemic nephropathy in man. Clin. Nephrol. 7, 112–119 (1977).
Sontia, B., Montezano, A. C., Paravicini, T., Tabet, F. & Touyz, R. M. Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. Hypertension 51, 915–921 (2008).
Winter, C., Schulz, N., Giebisch, G., Geibel, J. P. & Wagner, C. A. Nongenomic stimulation of vacuolar H+-ATPases in intercalated renal tubule cells by aldosterone. Proc. Natl Acad. Sci. USA 101, 2636–2641 (2004).
Gregoire, J. R. Adjustment of the osmostat in primary aldosteronism. Mayo Clin. Proc. 69, 1108–1110 (1994).
Bobrie, G. et al. Autosomal dominant polycystic kidney disease with primary hyperaldosteronism. Nephrol. Dial. Transplant. 7, 647–650 (1992).
Gejyo, F., Ishida, K. & Arakawa, M. Autosomal dominant polycystic kidney disease complicated by primary aldosteronism. Case report and review of the literature. Am. J. Nephrol. 14, 236–238 (1994).
Rajasoorya, Chee, T. S. & Ng, B. K. Hypertension in disguise—a trap for the unwary. Eur. J. Endocrinol. 133, 93–96 (1995).
Torres, V. E., Young, W. F. Jr, Offord, K. P. & Hattery, R. R. Association of hypokalemia, aldosteronism, and renal cysts. N. Engl. J. Med. 322, 345–351 (1990).
Novello, M. et al. Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment. J. Hypertens. 25, 1443–1450 (2007).
Perey, D. Y., Herdman, R. C. & Good, R. A. Polycystic renal disease: a new experimental model. Science 158, 494–496 (1967).
Brown, J. J. et al. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br. Med. J. 2, 729–734 (1972).
Ghose, R. P., Hall, P. M. & Bravo, E. L. Medical management of aldosterone-producing adenomas. Ann. Intern. Med. 131, 105–108 (1999).
Stowasser, M. & Gordon, R. D. Primary aldosteronism: learning from the study of familial varieties. J. Hypertens. 18, 1165–1176 (2000).
Acknowledgements
Written consent for publication was obtained from the patient.
Author information
Authors and Affiliations
Contributions
E. J. Hoorn wrote the initial first draft; all of the authors researched data for the article and contributed to the discussion of content, and reviewed/edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hoorn, E., Hesselink, D., Kho, M. et al. A case of primary aldosteronism revealed after renal transplantation. Nat Rev Nephrol 7, 55–60 (2011). https://doi.org/10.1038/nrneph.2010.158
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2010.158
This article is cited by
-
New treatment paradigms for ADPKD: moving towards precision medicine
Nature Reviews Nephrology (2017)